Copyright
©The Author(s) 2023.
World J Clin Cases. Jun 16, 2023; 11(17): 4202-4209
Published online Jun 16, 2023. doi: 10.12998/wjcc.v11.i17.4202
Published online Jun 16, 2023. doi: 10.12998/wjcc.v11.i17.4202
Table 2 Crohn’s disease and human immunodeficiency virus treatment (in August)
Inpatient treatment | |||||
Crohn’s disease exacerbation treatment | HIV treatment | ||||
Prednisolone | 30 mg × 1 | 5 mg/wk | Emtricitabine/tenofovir disoproxil | 200 mg/245 mg × 1 | |
Metronidazole | 500 mg × 3 | Dolutegravir | 50 mg × 1 | ||
Mesalazine | 2000 mg × 2 | ||||
Azathioprine | 50 mg × 2 | ||||
Outpatient treatment | |||||
Crohn’s disease treatment | HIV treatment | ||||
Prednisolone | Eventually discontinued | Emtricitabine/tenofovir disoproxil | 200 mg/245 mg × 1 | ||
Mesalazine | 2000 mg × 2 | Dolutegravir | 50 mg × 1 | ||
Azathioprine | 50 mg × 2 |
- Citation: Vinikaite A, Kurlinkus B, Jasinskaite D, Strainiene S, Buineviciute A, Sadauskaite G, Kiudelis V, Kazenaite E. Crohn’s disease in human immunodeficiency virus-infected patient: A case report. World J Clin Cases 2023; 11(17): 4202-4209
- URL: https://www.wjgnet.com/2307-8960/full/v11/i17/4202.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i17.4202